Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2022 Apr 1;21(4):502–510. doi: 10.1158/1535-7163.MCT-21-0016

Figure 5: Effect of J007 in vivo.

Figure 5:

A) Mice (8/group; 6 female, 2 male) challenged SQ w/ WT control cells or A1-deleted 111 cells and treated +/− daily IP injections of J007 at 20 mg/kg; J007 significantly (p<0.01) inhibited growth of WT cells but had no effect on 111 growth; B) Immunoblot of myc expression in tumors obtained from mice shown in figure 5A; *=significantly inhibited (p<0.01) vs non-treatment; C) Survival of mice (5 mice/group; 3 female, 2 male) challenged with SQ tumors and treated +/− J007 with daily injections for 15 days; J007 significantly prolonged survival at both doses (p=0.0018); D) Bioluminescence of mice challenged with IV tumor cells, treated with vehicle or J007 and imaged day 28; Treatment was started day +7 after inoculation and continued until day +28; E) ROI signal of experiment shown in fig ‘D’; F) Survival of mice from experiment shown in ‘D’ (6 mice/group, 3 female, 3 male); G) Electrophoresis of serum from B cell-deficient NOD/SCID mice challenged IV with MM cells and treated as in fig 5F. Each lane comprises pooled sera from 3 mice in each group. “NOD/SCID” lane from non-tumor-bearing mice (gamma globulin fraction is ‘empty’ as mice are B cell deficient).